The purpose of this study is to investigate whether brain responses within the subgenual anterior cingulate cortex (sgACC) are associated with clinical improvement following transcranial magnetic stimulation (TMS) treatment in individuals with depression. Participants will be randomized to receive either active or sham intermittent theta-burst stimulation (iTBS) delivered to an individualized, fMRI-guided cortical target over a 6-week treatment course. The study will examine whether sgACC responses measured using interleaved TMS and functional magnetic resonance imaging (TMS/fMRI) before treatment predict antidepressant response and whether changes in sgACC responses throughout treatment are associated with changes in depressive symptoms. Study participation will include clinical interviews, questionnaires, MRI scans, interleaved TMS/fMRI sessions conducted before, during, and after treatment, and weekday TMS sessions for approximately 6 weeks.

This research study is being conducted to determine the feasibility of delivering FLASH ultra-high dose-rate proton-therapy (ConformalFLASH) to patients requiring reirradiation of their head and neck cancer.

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC. We would like to rely on WCG IRB as the IRB of Record for this study.

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.